An early-stage venture capital based in the United States focuses on digital health and AI-enabled healthcare technologies designed to shift healthcare from reactive treatment toward prevention, early diagnostics, and long-term disease management. The firm invests across Pre-Seed through Series A stages using both equity and SAFE structures, with typical check sizes ranging from approximately $200K to $2M. Geographically, the firm focuses on health technology companies expanding into the U.S. market, with particular interest in companies operating on the U.S. East Coast and internationally connected healthcare startups. The firm provides hands-on go-to-market support through a broad healthcare network that assists portfolio companies with U.S. commercialization and market-entry strategy.
The firm is interested in a wide range of digital health and AI-driven healthcare solutions. Core thematic interests include mental health and well-being, women’s health and femtech, chronic disease management, musculoskeletal health, and senior care. The firm also actively evaluates AI-powered diagnostics and clinical decision-support technologies, behavior change and patient engagement platforms, remote patient monitoring solutions with predictive capabilities, prevention and early-detection technologies, and clinically validated digital therapeutics.
From a company and management team perspective, the firm does not impose strict requirements regarding company structure or leadership composition.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment